RESEARCH ARTICLE

The longitudinal association between depression, anxiety symptoms and HIV outcomes, and the modifying effect of alcohol dependence among ART clients with hazardous alcohol use in Vietnam

Minh X Nguyen1,§, H. Luz McNaughton Reyes1, Brian W Pence2, Kate Muessig1, Heidi E Hutton3, Carl A Latkin4, David Dowdy5, Geetanjali Chander6, Kathryn E Lancaster7, Constantine Frangakis8, Teeada Sripaipan1, Viet Ha Tran1 and Vivian F Go1

§Corresponding author: Minh X Nguyen, Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Tel: +1 84962275890. (binhminh@live.unc.edu)

Abstract

Introduction: Mental health disorders may negatively impact HIV outcomes, such as viral suppression (VS) and antiretroviral (ART) adherence among people with HIV (PWH) with hazardous alcohol use. This study evaluates the longitudinal association between depression, anxiety symptoms, VS and complete ART adherence among ART clients with hazardous alcohol use in Vietnam; and examines alcohol dependence as a modifier in this association.

Methods: This was a secondary data analysis of a trial for hazardous drinking ART clients in Thai Nguyen, Vietnam. From March 2016 to May 2018, 440 ART clients with an Alcohol Use Disorders Identification Test-Concise (AUDIT-C) score >4 for men and >3 for women were enrolled. Individuals were randomized to either a combined intervention, a brief intervention or a standard of care. Data on sociodemographics, depression, anxiety symptoms, alcohol use, VS and ART adherence were collected at baseline, three, six, and twelve months. Generalized estimating equation models controlling for intervention exposure were used to estimate time-lagged associations. Risk ratios were estimated using Poisson regression with robust variance estimation.

Results: The mean age of participants was 40.2. The majority was male (96.8%), had at least some secondary school education (85.0%) and had a history of injection drug use (80.9%). No overall effect of depression and anxiety symptoms on VS was observed. When stratified by time, increased anxiety symptoms at six months were associated with VS at 12 months (adjusted risk ratio (aRR) = 1.09; 95% CI 1.02 to 1.17). An increase in depression or anxiety symptoms was associated with a decreased probability of complete ART adherence (depression symptoms: aRR = 0.95; 95% CI: 0.91 to 0.99; anxiety symptoms: aRR = 0.93; 85% CI: 0.88 to 0.99). The negative effects of anxiety symptoms on ART adherence were stronger among participants with alcohol dependence, compared to those without.

Conclusions: Depression and anxiety symptoms had no overall effect on VS, although they were associated with a lower probability of complete ART adherence. Interventions focusing on mental healthcare for PWH with hazardous alcohol use are needed, and integration of mental healthcare and alcohol reduction should be implemented in HIV primary care settings.

Keywords: mental health; depression; anxiety; HIV; hazardous alcohol use; viral suppression; adherence; Vietnam

Additional Supporting information may be found online in the Supporting Information tab for this article.

1 INTRODUCTION

People with HIV (PWH) are disproportionately affected by depression and anxiety disorders [1-3]. Indeed, PWH are 1.6 to 4 times more likely to be diagnosed with depression and anxiety disorders than HIV-negative individuals [4-9]. For example a global systematic review reported a prevalence of depression among PWH ranging from 15% to 44%, depending on the region [10,11]. The presence of anxiety or depression symptoms among PWH has numerous implications for HIV outcomes. The Transactional Model of Stress and Coping suggests that the experience of stress can have a negative impact...
on physical health and functional status through direct physiological impacts on health or through indirect effects via maladaptive behaviours, such as non-adherence to medications [12]. Depression and anxiety symptoms among PWH are associated with poor viral load outcomes [3,13-16] and lower odds of achieving antiretroviral therapy (ART) adherence [17-19]. PWH with depression and anxiety symptoms generally have faster progression to AIDS and higher mortality rates [20-24].

Hazardous drinking is defined as the quantity and pattern of alcohol consumption that increases adverse health outcomes, while alcohol dependence – a higher level of alcohol use disorder – is defined as a strong desire to consume alcohol, difficulties in controlling its use, and persistent use despite harmful consequences [25,26]. An estimated 25% to 50% of PWH are hazardous drinkers [27-29], and about 10.6% of PWH had both depression symptoms and harmful levels of alcohol use [30]. PWH with hazardous alcohol use are even more vulnerable to mental disorders than PWH without drinking issues [31], and they mayhave unique challenges that make abstinence difficult. For example a study among PWH in Vietnam showed that participants were particularly susceptible to alcohol abstinence stigma, which was also associated with higher levels of alcohol use [32]. Therefore, it is essential to understand how depression and anxiety symptoms affect viral suppression (VS) and ART adherence among PWH with hazardous alcohol use. However, there is a dearth of research on the associations between depression, anxiety and HIV outcomes among this subgroup of PWH.

According to the Syndemics Theory, the co-existence and synergistic interaction of more than one adverse condition in a patient can produce worse health outcomes than each condition independently [33,34]. While mental health symptoms are independently associated with poorer HIV outcomes, alcohol use can also accelerate HIV progression through a number of mechanisms. High levels of alcohol use do not only negatively impact ART adherence and response to medication but can also lead to compromised liver function and liver diseases [35-42]. Therefore, mental health symptoms and high levels of alcohol use can substantially increase the risk of treatment failure among PWH [43]. The interrelationship between these comorbidities and HIV outcomes among PWH remains largely unknown. The understanding of how these comorbidities interact will shed light on the need for a more holistic approach to addressing psychological and substance use comorbidities for PWH.

In Vietnam, alcohol is accessible and affordable, and excessive alcohol consumption is common during social and business gatherings [44,45]. A study among 1016 PWH in Vietnam found that 30.1% of PWH had hazardous alcohol use [46]. Vietnamese PWH are also commonly affected by mental health disorders such as depression and anxiety [47,48]. Using data from a randomized controlled trial of two alcohol reduction interventions among PWH with hazardous alcohol use in Vietnam, we aim to [1] evaluate the longitudinal association between mental health symptoms (depression and anxiety symptoms) and two HIV outcomes (VS and complete ART adherence) among ART clients with hazardous alcohol use in Vietnam; and [2] determine whether alcohol dependence modifies the longitudinal association between depression, anxiety symptoms and HIV outcomes (conceptual model shown in Figure S1).

2 | METHODS

2.1 | Study design and study population

This research is a secondary data analysis of the parent study, Reducing Hazardous Alcohol Use & HIV Viral Load: A Randomized Controlled Trial in Antiretroviral Treatment (ART) Clinics in Vietnam [REDART; NCT02720237]. REDART is a three-arm RCT conducted from March 2016 to May 2018 among ART clinic patients with hazardous alcohol use in Thai Nguyen – a mountainous, multi-ethnic province located in Northeast Vietnam [49]. Mirroring Vietnam’s broader epidemic, HIV transmission in Thai Nguyen is primarily driven by injection drug use, with an HIV prevalence among people who inject drugs of 31.2% [50]. The main goal of the parent study was to understand the relative effectiveness of two interventions based on Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) in improving alcohol- and HIV-related outcomes [49]. Four hundred and forty PWH with hazardous alcohol use were randomly assigned to receive either a combined intervention, a brief intervention or a standard of care assessment control (Figure 1). Participants were recruited from six ART community clinics and 1 ART hospital clinic. The World Health Organization (WHO) Alcohol Use Disorders Identification Test-Concise (AUDIT-C) survey, which had been utilized in previous studies in Vietnam [46,51-54], was used to assess eligibility [55]. Men and women who scored ≥4 (men) or ≥3 (women) on the AUDIT-C were considered eligible [55]. Additional inclusion criteria were as follows: (1) being a current ART client; (2) being ≥18 years of age and (3) planning to reside in Thai Nguyen for the next 24 months. Exclusion criteria were as follows: (1) inability to provide informed consent due to cognitive impairment or having threatening behaviour (study staff assessed sobriety); (2) unwilling to provide locator information or (3) currently participating in other HIV, drug use or alcohol programme, study or intervention. Survey data, along with viral load data were collected at baseline, three, six and twelve months after the intervention. All questionnaires were administered in Vietnamese. The study was reviewed and approved by the University of North Carolina at Chapel Hill’s Institutional Review Board (IRB) and the IRB at the Thai Nguyen Center for Preventive Medicine.

The combined and brief interventions were associated with a significant improvement of the primary outcome – percent days abstinent, compared to the standard of care group at 12 months. VS (<20 copies of HIV-1 RNA per millilitre) at 12 months was also higher after the brief intervention than the standard of care. Details of the main trial were published elsewhere [49].

2.2 | Measurements

2.2.1 | Depression and anxiety symptoms

At all visits, depression symptoms were assessed with the Patient Health Questionnaire-9 (PHQ-9) scale [56] and anxiety symptoms were assessed with the Generalized Anxiety Disorder-7 (GAD-7) scale [57,58]. In Vietnam, the PHQ-9 scale has shown good convergent validity, construct validity as well as reliability [59], and has been used for a range of
populations, including PWH [60-62]. Nine items assess how often depression symptoms including loss of interest or pleasure in doing things or feeling down or depressed occurred in the last two weeks. The GAD-7 scale has not been formally validated in Vietnam but has been used in different Vietnamese populations to measure anxiety [63,64]. This scale has seven items that evaluate the frequency of symptoms such as feeling nervous, anxious, or on edge or not being able to stop or control worrying. For both the PHQ-9 and GAD-7, a cut-off score of 5 can be interpreted as having mild levels of symptoms that are consistent with depression and anxiety respectively [56,65]. The maximum scores for depression and anxiety symptoms were 27 and 21 respectively. Since classifying continuous data into binary data can result in a loss of power and binary data are less sensitive to change [66], the original continuous scores of depression and anxiety symptoms were used in this study. Depression and anxiety symptoms were rescaled so that the reported estimates of association reflect the change in outcome associated with a 5-unit change in the continuously measured PHQ-9 or GAD-7 score. We performed this rescaling because a 1-unit change in each score is not clinically meaningful, whereas a 5-unit change is considered potentially clinically significant, implying that a participant has moved from one level of severity to the next [67,68]. This rescaling method has been used in other studies using continuous measures of depression and anxiety symptoms [69,70].

2.2.2 | Alcohol dependence

Alcohol dependence was evaluated with the Mini International Neuropsychiatric Interview (MINI) questionnaire [71] – a 7-item structured diagnostic psychiatric interview in which endorsing three or more items indicates alcohol dependence [72].

2.2.3 | VS and ART adherence

Viral load was measured by HIV-1 ribonucleic acid (RNA) levels using the in vitro nucleic acid amplification test (COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test). VS was defined as having less than 20 copies/ml. Complete ART adherence (self-reported) was defined as no missed pills in the past three months. Both HIV viral load and self-reported adherence were measured at baseline, three-, six- and twelve-month follow-ups. Since ART adherence is subject to social desirability bias [73], VS was considered the primary outcome of interest in this study.

2.2.4 | Demographics and other covariates

Standard demographics were collected at baseline (e.g. age, marital status, education, employment). Based on the literature, the following covariates were chosen a priori as potential confounders: age, sex, education, marital status, employment, alcohol dependence, non-injection drug use, injection drug use, social support, HIV stigma and intimate partner violence [16,74-81]. Participants were asked if they had used any types of non-injection drugs (including heroin, methamphetamines, etc.) in the last three months and if they had ever injected drugs in the past. Social support was measured with a 5-question modified version of the Medical Outcomes Study Social Support Instrument [82] used previously by our research group among PWH in Vietnam [83]. Based on the distribution of the social support score at baseline, the social support level was classified into four quartiles. To evaluate HIV stigma, participants were asked to state their levels of agreement with four statements indicating internalized, experienced or anticipated HIV stigma. They were classified as having HIV stigma if they reported any level of agreement with
any of the four statements. Participants were classified as having ever experienced intimate partner violence if they had ever been a victim of physical, emotional or sexual abuse in an intimate relationship.

2.3 Statistical analysis

Means (standard deviations [SD]) of continuous variables and proportions of categorical variables were reported. Generalized estimating equations (GEE) models were used to estimate the time-lagged associations between depression, anxiety symptoms and two HIV outcomes: VS and complete ART adherence. We conducted lagged analyses of the association between mental health symptoms at a given visit and HIV outcomes at the following visit. In this paper, time refers to the time of outcome assessment, which included: three-month, six-month or twelve-month follow-up visits. We estimated risk ratios (RR) of VS and ART adherence associated with a 5-unit change in scores of depression and anxiety symptoms, as other studies have [69,70]. Since depression and anxiety symptoms were highly correlated in our sample, for each outcome, separate models with the same set of covariates were run for depression or anxiety symptoms as the main predictor. Since HIV outcomes in the sample were very common (Table 1), the associations were explored using Poisson regression with robust variance estimation to avoid biases associated with inflated odds ratios [84]. Exchangeable covariance matrix between repeated measures was selected because it did not have convergence issues and had the smallest Quasi-likelihood Information Criterion (QIC) [85].

We assessed whether alcohol use modified the associations between mental health symptoms and HIV outcomes by adding interaction terms (e.g. depression symptoms × alcohol dependence) to the model. Similarly, the interactions between assessment time point and mental health symptoms were tested (e.g. depression symptoms × three-month visit). Since the longitudinal effects of mental health symptoms on VS may vary by baseline VS, baseline VS was also examined as a potential effect modifier. Interactions with product terms not significantly different from 0 (at p < 0.05 using the Wald test) were not included in the multivariable regression models. Significant modification effects were further explored by probing the associations of interest within the stratum of the effect modifiers (controlling for confounders). Only covariates associated with the outcome at p < 0.1 in the univariable models and meaningfully changed the main estimates of association (by more than 10%) were included in the final models [86,87]. Intervention exposure and time stratum of the effect modifiers (controlling for confounders).

Table 1. Participants’ baseline characteristics, stratified by viral suppression and ART adherence at baseline

| Characteristics                  | Complete ART adherence at baseline | Viral suppression at baseline | Total (N = 440) |
|----------------------------------|------------------------------------|------------------------------|----------------|
|                                  | Yes (N = 334)                      | No (N = 103)                 | Yes (N = 370)  | No (N = 70)  |
| Age (years) (mean ± SD)          | 40.8 ± 5.6                         | 38.2 ± 5.8                   | 40.3 ± 5.6    | 39.9 ± 6.6   | 40.2 ± 5.8   |
| Male                             | 322 (96.4)                         | 101 (98.1)                   | 361 (97.6)    | 65 (92.9)    | 426 (96.8)   |
| Education                        |                                    |                              |               |              |
| Primary school or less           | 51 (15.3)                          | 14 (13.6)                    | 55 (14.9)     | 11 (15.7)    | 66 (15.0)    |
| Some secondary school            | 191 (57.2)                         | 53 (51.5)                    | 201 (54.3)    | 45 (64.3)    | 246 (55.9)   |
| Some high school                 | 66 (19.8)                          | 20 (19.4)                    | 76 (20.5)     | 10 (14.3)    | 86 (19.6)    |
| Some technical training, college or university | 26 (7.8)                          | 16 (15.5)                    | 38 (10.3)     | 4 (5.7)      | 42 (9.6)     |
| Marital status                   |                                    |                              |               |              |
| Not married                      | 54 (16.2)                          | 25 (24.3)                    | 67 (18.1)     | 12 (17.1)    | 79 (18.0)    |
| Married                          | 245 (73.4)                         | 57 (55.3)                    | 261 (70.5)    | 44 (62.9)    | 305 (69.3)   |
| Widowed, divorced or separated   | 35 (10.5)                          | 21 (20.4)                    | 42 (11.4)     | 14 (20.0)    | 56 (12.7)    |
| Non-injection drug use (Yes)     | 273 (81.2)                         | 81 (78.6)                    | 297 (80.3)    | 60 (85.7)    | 357 (81.1)   |
| Alcohol dependence (Yes)         | 125 (37.4)                         | 46 (44.7)                    | 145 (39.2)    | 27 (38.6)    | 172 (39.1)   |
| Ever experienced, internalized or anticipated HIV stigma (Yes) | 55 (16.5) | 36 (35.0) | 82 (22.2) | 11 (15.7) | 93 (21.1) |
| Ever experienced intimate partner violence (Yes) | 200 (59.9) | 68 (66.0) | 230 (62.2) | 40 (57.1) | 270 (61.4) |
| Social support (mean ± SD)       | 64.6 ± 28.9                        | 61.1 ± 29.6                  | 64.4 ± 29.2   | 60.7 ± 28.6  | 63.3 ± 29.2  |
| Depression symptoms (mean ± SD)  | 2.6 ± 3.5                          | 3.8 ± 4.2                    | 2.9 ± 3.7     | 2.9 ± 3.9    | 2.9 ± 3.7    |
| Anxiety symptoms (mean ± SD)     | 1.3 ± 2.5                          | 2.4 ± 3.6                    | 1.5 ± 2.8     | 1.9 ± 3.1    | 1.6 ± 2.8    |

ART, antiretroviral therapy; SD, standard deviation.

aFive participants had missing data on intimate partner violence at baseline.
3.1 Sample characteristics at baseline

The mean age of enrolled participants (n = 440) was 40.2 years old (SD = 5.8) (Table 1). Almost all participants were male (96.8%), and 85% had at least some secondary school education. More than two-thirds (69.3%) were married, and 81.1% were employed at baseline. Most participants had a history of injection drug use (80.9%), and 39.1% had used non-injection drugs in the past three months. Alcohol dependence based on the MINI score was identified among 21.1% of participants. More than half had ever experienced HIV stigma (61.4%), and 37.5% had ever experienced intimate partner violence. The mean social support score was 63.3 (SD = 29.3, scale 0 to 100).

At baseline, 84.1% were virally suppressed and 76.4% had not missed an ART pill in the last three months. There was no difference in depression symptoms between participants with and without VS at baseline. A slightly lower score for anxiety symptoms was observed among those with VS (Table 1). Those who completely adhered to their ART regimen at baseline had lower depression and anxiety symptoms scores, compared to those without complete adherence.

3.2 Distribution of depression, anxiety symptoms and HIV outcomes over time

Figure 2 shows changes in mental health symptoms, VS and ART adherence of the whole sample over time. There is a decrease in observed depression and anxiety symptoms from baseline to 12-month follow-up. There were no significant changes in VS over time, whereas complete ART adherence increased from 76.4% at baseline to 84.8% at the last follow-up.

3.3 Associations between depression, anxiety symptoms and HIV outcomes

Overall, there were no associations between mental health symptoms and VS. However, a 5-point increase in depression or anxiety symptoms score was associated with a lower probability of complete ART adherence at the next visit (depression symptoms: aRR = 0.95; 95% CI: 0.91 to 0.99; anxiety symptoms: aRR = 0.93; 85% CI: 0.88 to 0.99) (Table 2). There was a significant effect modification by time, and the strength and significance of the associations between anxiety symptoms and HIV outcomes varied across study time points. Estimates of the full models with p-values of interaction terms are presented in Supplementary File, Table S1.
Table 3. Associations between depression, anxiety symptoms and HIV outcomes at the next visit, stratified by time of outcome assessment

| Time of outcome assessment | Models predicting viral suppressionb | Models predicting complete ART adherencec |
|---------------------------|------------------------------------|----------------------------------------|
|                           | aRR | 95%CI | p-values | aRR | 95%CI | p-values |
| Main predictor: depression symptoms |     |      |         |     |      |         |
| At three-month visit      | 0.99 | 0.94 to 1.04 | 0.66 | 0.90 | 0.84 to 0.97 | 0.005 |
| At six-month visit        | 0.97 | 0.91 to 1.03 | 0.31 | 0.96 | 0.89 to 1.03 | 0.28 |
| At twelve-month visit     | 1.05 | 1.00 to 1.10 | 0.09 | 1.01 | 0.94 to 1.09 | 0.69 |
| Main predictor: anxiety symptoms |     |      |         |     |      |         |
| At three-month visit      | 0.96 | 0.89 to 1.03 | 0.30 | 0.87 | 0.79 to 0.96 | 0.005 |
| At six-month visit        | 0.96 | 0.86 to 1.07 | 0.50 | 0.90 | 0.79 to 1.03 | 0.14 |
| At twelve-month visit     | 1.09 | 1.02 to 1.17 | 0.02 | 1.04 | 0.96 to 1.13 | 0.36 |

ART, antiretroviral therapy; aRR, adjusted risk ratio; CI, confidence interval.

bModels with the same outcome have the same set of covariates. Time presented in the first column is the time of assessment of viral suppression.

cModels controlling for marital status, alcohol dependence at baseline, adherence at baseline, intervention exposure, time, interaction of time x depression/anxiety symptoms.

dEach multivariable model has only one mental health predictor, either depression symptoms or anxiety symptoms at the previous time point. Models with the same outcome have the same set of covariates. Time presented in the first column is the time of assessment of viral suppression. 

eModels predicting vs control for age, viral suppression at baseline, intervention exposure, time, interaction of time x depression/anxiety symptoms.

stratified by time, both baseline depression and anxiety symptoms were associated with a lower probability of complete ART adherence at three months (depression symptoms: aRR = 0.90; 95%CI: 0.84 to 0.97; anxiety symptoms: aRR = 0.87; 85%CI: 0.79 to 0.96), though no association was seen with VS. At subsequent follow-up visits, there was no association between symptoms of depression and anxiety with either VS or complete ART adherence, except for a signal of higher VS at 12 months associated with a 5-point increase in anxiety symptoms at six months (aRR = 1.09; 95%CI 1.02 to 1.17) (Table 3). Baseline VS was not a significant modifier of the associations between depression, anxiety and VS (Tables S2.1 and S2.2).

3.4 Associations between depression/anxiety symptoms and HIV outcomes: Possible modification role of alcohol dependence

Alcohol dependence at baseline significantly modified the association between anxiety symptoms and complete ART adherence (p-value for interaction term = 0.02). Anxiety symptoms at baseline and lower probability of complete adherence at three months were more strongly related among participants with alcohol dependence, compared to those without (Table 4). Anxiety symptoms only predicted poor adherence at six months among those with alcohol dependence. At 12 months, there was no association between anxiety at the previous time point and adherence for all participants. The interactions between alcohol dependence and mental health symptoms in the remaining associations (depression predicting both HIV outcomes and anxiety predicting VS) were not significant at p < 0.05 and were not further explored.

4 DISCUSSION

Among a sample of 440 ART clients with hazardous alcohol use, we did not find an overall effect of depression and anxiety symptoms on VS, but observed a decreased probability of complete ART adherence associated with increased depression and anxiety symptoms. The magnitude and significance of the associations varied by the time of outcome assessment. Negative effects of anxiety symptoms on ART adherence were significantly worse among participants with alcohol dependence at baseline, compared to those without alcohol dependence.

While there was no effect of mental health symptoms on VS when all time points were taken into account, we found that anxiety symptoms were associated with a small increase in the probability of VS at the last follow-up. This was an
unexpected finding, although one study among PWH in Russia also reported that a greater state of anxiety was positively associated with better adherence [16]. Previous studies also reported that a greater state of anxiety was positively unexpected finding, although one study among PWH in Russia also reported overwhelming proportions of participants being male with drug use behaviours [46,53]. Finally, in this study, we reported aRRs associated with a 5-unit change in depression and anxiety symptoms. We acknowledge that there are alternative ways to analyse PHQ-9 and GAD-7 scores, which might result in different estimates of the associations between mental health symptoms and HIV outcomes than ours.

Our findings suggest that increased depression or anxiety symptoms over time are associated with decreased ART adherence among PWH with hazardous alcohol use, and support a modifying effect of alcohol dependence on the association between anxiety symptoms and ART adherence in this group. We recommend that future interventions aim to raise awareness about mental health problems among PWH, especially those with alcohol use disorders. Mental health services such as screening, counselling or medication treatment are also imperative to improve HIV outcomes for PWH with hazardous alcohol use. These mental health services can be integrated into alcohol use interventions or into existing HIV primary care clinics in Vietnam. It is also important that these interventions are tested for efficacy and cost-effectiveness in low-resource settings such as Vietnam.

5 | CONCLUSIONS

Depression and anxiety symptoms had no overall effect on VS, although anxiety symptoms at six months were associated with a mild increase in the probability of VS at 12 months. Increased depression and anxiety symptoms were associated with a lower probability of complete ART adherence, and participants with both alcohol dependence and anxiety symptoms had the lowest adherence. Interventions focusing on mental healthcare for PWH with hazardous alcohol use are much needed, and optimal models integrating mental healthcare and alcohol reduction should be implemented and tested in HIV primary care clinics in low-resource settings.

AUTHORS’ AFFILIATIONS

1Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 3Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 4Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 5Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 6Department of Epidemiology, College of Public Health, Ohio State University, Columbus, OH, USA; 7Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

COMPETING INTEREST

The authors have declared no conflict of interest.

AUTHORS’ CONTRIBUTIONS

V.G., C.L., H.H., G.C., K.L., T.S., H.T. and D.D. performed the research. V.G., C.L., H.H., G.C., K.L., D.D. and C.F. designed the research study. M.N. analysed the data and wrote the paper. V.G., H.L.R., B.P. K.M., C.L., D.D., H.H., G.C. and K.L.
revised it critically for important intellectual authors. All authors have given final approval of the manuscript to be published.

ACKNOWLEDGEMENTS

This study was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R01DA037440. This publication resulted [in part] from research supported by the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR), an NIH funded program. We are grateful for the support in conducting this trial offered by the Thai Nguyen Center for Disease Control. We also thank all ART clients in the seven clinics for their participation in the study.

REFERENCES

1. Adams C, Zacharia S, Masters L, Coffey C, Catalan P. Mental health problems in people living with HIV: changes in the last two decades: the London experience 1990–2014. AIDS Care. 2016;28 Suppl 1:56–9.
2. Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70(4):505–11.
3. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr. 2006;42(3):298–306.
4. Chipiro PJ, Fylkesnes K. Mental distress in the general population in Zambia: impact of HIV and social factors. BMC Public Health. 2007;7:298.
5. Keel MK, Lee SY, Kim NY, Lee JS, Kim JM, Choi JY, et al. Anxiety and depressive symptoms among patients infected with human immunodeficiency virus in South Korea. AIDS Care. 2015;27(9):1174–82.
6. Maj M, Janssen R, Starace F, Zaudig M, Satz P. Sughondhabhirom B, et al. WHO Neuropsychiatric AIDS study, cross-sectional phase I: Study design and psychiatric findings. Arch Gen Psychiatry. 1994;51(3):39–49.
7. Moore CL, Grulich AE, Prestage G, Gidding HF, Jin F, Petoumenos K, et al. Hospitalization for Anxiety and Mood Disorders in HIV-infected and - Uninfected Gay and Bisexual Men. J Acquir Immune Defic Syndr. 2016;73(5):589–97.
8. Jallow A, Ljunggren G, Wandell P, Carlsson AC. Prevalence, incidence, mortality and co-morbidities amongst human immunodeficiency virus (HIV) patients in Stockholm County, Sweden – the Greater Stockholm HIV Cohort Study. AIDS Care. 2015;27(2):142–9.
9. Kendall CE, Wong J, Taljaard M, Glazier RH, Hogg W, Younger J, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;14:161.
10. Lofgren SM, Bond DJ, Nakasui J, Boulware DR. Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa: Systematic Review and Meta-analysis. AIDS Behav. 2020;24(4):1752–64.
11. Rezaei S, Ahmad S, Rahmati J, Hoseinifard H, Dehnavi A, Aryankhesal A, et al. Global prevalence of depression in HIV/AIDS: a systematic review and meta-analysis. BMJ Support Palliat Care. 2019;9(4):404.
12. Glanz K, Rimer BK, Viswanath K. Health Behavior: Theory, Research, and Practice, 5th Edition. San Francisco: Jossey-Bass, 2008. Chapter 12: Stress, coping and response to highly active antiretroviral therapy in women. J Acquir Immun Defic Syndr. 2008;48(9):2059–2071.
13. Abas M, O’Clerigh C. Global mental health and the ambition to end AIDS by 2030. Lancet Psychiatry. 2018;5(11):867–9.
14. Kingeri C, Haile ZT, Ngatia P. Depression symptoms, social support and overall health among HIV-positive individuals in Kenya. Int J STD AIDS. 2015;26(3):165–72.
15. Nanne D, Caruso R, Mitchell AJ, Meggilloari E, Grassi L. Depression in HIV-infected patients: a review. Current Psychiatry Reports. 2014;17(1):530.
16. So-Amnah K, Gupta SK, Kundu S, Stewart JC, Goulet JL, Butt AA, et al. Depression and all-cause mortality risk in HIV-infected and HIV-uninfected US veterans: a cohort study. HIV Med. 2019;20(5):317–29.
17. Yousaf S, Mohd Ariffin SR, Musa R, Md Isa ML. Depression and HIV disease progression: a mini-review. Clin Pract Epidemiol Mental Health. 2019;15:153–9.
18. Reid MC, Fiellin DA, O’Connor PG. Hazardous and harmful alcohol consumption in primary care. Arch Intern Med. 1999;159(15):1681–9.
19. National Collaborating Centre for Mental Health (UK). Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. Leicester (UK): British Psychological Society; 2011. (NICE Clinical Guidelines, No. 113.) 2. ALCOHOL DEPENDENCE AND HARMFUL ALCOHOL USE. 2011.
20. Sarvetberg MJ, Leyden WA, Leibowitz A, Hare CB, Jing HJ, Sterling S, et al. Factors associated with hazardous alcohol use and motivation to reduce drinking among HIV primary care patients: Baseline findings from the Health & Motivation study. Addict Behav. 2018;84:110–7.
21. Veld DHI, Pengpid S, Colebunders R, Skaal L, Peltzer K. High-risk alcohol use and associated socio-demographic, health and psychosocial factors in patients with HIV infection in three primary health care clinics in South Africa. Int J STD AIDS. 2017;28(7):651–9.
22. da Silva CM, Mendoza-Sassi RA, da Mota LD, Nader MM, de Martinez AM. Alcohol use disorders among people living with HIV/AIDS in Southern Brazil: prevalence, risk factors and biological markers outcomes. BMC Infect Dis. 2017;17(1):263.
23. Braithwaite RS, Fang Y, Tate J, Mentor SM, Bryant KJ, Fiellin DA, et al. Do alcohol misuse, smoking, and depression vary concordantly or sequentially? A longitudinal study of HIV-infected and matched uninfected veterans in care. AIDS Behav. 2016;20(3):566–72.
24. Sullivan LE, Goulet JL, Justice AC, Fiellin DA. Alcohol consumption and depressive symptoms over time: a longitudinal study of patients with and without HIV infection. Drug Alcohol Depend. 2011;117(2–3):158–63.
25. Lancaster KE, Hetrick S, Sripanidkulchai T, Ha TV, Hutton HE, Chander G, et al. Alcohol abstinence stigma and alcohol use among HIV patients in Thai Nguyen, Vietnam. PLoS One. 2020;15:e0239330.
26. Singer M. Introduction to syndemics: A critical systems approach to public and community health. New York, NY: John Wiley & Sons, Incorporated; 2009.
27. Singer M, Bulled N, Ostrach M, Bendenhall E. Syndemics and the biosocial conception of health. Lancet (London, England). 2017;389(10072):941–50.
28. Bilal U, Lau B, Lazo M, McCaul ME, Hutton HE, Sullivan MJ, et al. Interaction between alcohol consumption patterns, antiretroviral therapy type, and liver fibrosis in persons living with HIV. AIDS Patient Care STDs. 2016;30(5):200–7.
29. Bilal U, McCaul ME, Lau B, McCaul ME, Keruly J, Moore RD, Chang G. Effect of alcohol consumption on all-cause and liver-related mortality among HIV-infected individuals. HIV Med. 2017;18(5):332–41.
30. Conigliaro J, Hulz A, McGinnis KA, Rabeneck L, Justice AC. How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? J Acquir Immune Defic Syndr. 2003;33(4):521–5.
31. Justice AC, Lasky E, McGinnis KA, Skanderson M, Conigliaro J, Fultz SL, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care. 2006;44 B Suppl 2:550–62.
32. Kader R, Seedat S, Govender R, Kok JR, Parry CD. Hazardous and harmful use of alcohol and/or other drugs and health status among South African patients attending HIV clinics. AIDS Behav. 2014;18(5):525–31.
33. King C, Gang LM, Bart G, Kunkel L, Korthuis PT. HIV care continuum characteristics among people with opioid use disorder and HIV in Vietnam: baseline results from the BRAVO study. BMC Public Health. 2020;20(1):421.
34. Kresina TF, Flexner CW, Sinclair J, Correa MA, Stapleton JT, Adeniyi-Jones S, et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses. 2002;18(11):757–70.
43. Chicketo NE, Kundu S, Freiberg MS, Butt AA, Crystal S, So-Armah KA et al. Association of syndemic unhealthy alcohol use, cigarette use, and depression with all-cause mortality among adults living with and without HIV infection: veterans aging cohort study. Open Forum Infect Dis. 2019;6:ofz188.

44. Hershov RB, Zuskov DS, Vu Tuyet Mai N, Chander G, Hutton HE, Latkin C, et al. "[Drinking is] Like a Rule That You Can’t Break": perceived barriers and facilitators to reduce alcohol use and improve antiretroviral treatment adherence among people living with HIV and alcohol use disorder in Vietnam. Subst Use Misuse. 2016;51(7):1096–112.

45. Lincoln M, alcohol and drinking cultures in Vietnam: a review. Drug Alcohol Depend. 2016;159:1–8.

46. Tran BX, Nguyen N, Ohinmaa A, Duong AT, Nguyen LT, Van Hoang M, et al. Prevalence and correlates of alcohol use disorders during antiretroviral treatment in injection-driven HIV epidemics in Vietnam. Drug Alcohol Depend. 2013;127(1–3):39–44.

47. Levintov SN, Pence BW, Ha TV, Minh NL, Sriraipann T, Latkin CA, et al. Prevalence and predictors of depressive symptoms among HIV-positive men who inject drugs in Vietnam. PLoS One. 2018;13:e0191548.

48. Thai TT, Jones MK, Harris LM, Heard RC. The association between symptom’s of mental disorders and health risk behaviours in Vietnamese HIV positive outpatients: a cross-sectional study. BMC Public Health. 2017;17(1):250.

49. Go VF, Hutton HE, Ha TV, Chander G, Latkin CA, Mai NVT, et al. Effect of 2 interventions on alcohol abstinence and viral suppression among Vietnamese adults with hazardous alcohol use and HIV: a randomized clinical trial. JAMA Netw Open. 2020;3:e20171115.

50. Lim TW, Franjakis C, Latkin C, Ha TV, Minh NL, Zelaya C, et al. Community-level income inequality and HIV prevalence among persons who inject drugs in Thai Nguyen, Vietnam. PLoS One. 2014;9:e90723.

51. Giang KB, Spak F, Dzung TV, Allebeck P. The use of audit to assess level of alcohol problems in rural Vietnam. Alcohol Alcohol (Oxford, Oxfordshire). 2005;40(6):578–83.

52. Tran BX, Nguyen HLT, Le QN, Mai HT, Ngo C, Hoang CD, et al. Alcohol and tobacco use among methadone maintenance patients in Vietnamese rural mountainous areas. Addict Behav Rep. 2018;7:19–25.

53. Tran BX, Nguyen LT, Do CD, Nguyen QL, Maher RM, Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS. BMC Public Health. 2014;14:27.

54. Vu HM, Tran TT, Vu GT, Nguyen CT, Nguyen CM, Vu LG, et al. Alcohol use disorder among patients suffered from road collisions in a Vietnamese delta province. Int J Environ Res Public Health. 2019;16(13):2423.

55. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for alcohol use disorders and adherence to antiretroviral treatment and quality of life in injection drug users in a rural health district in North West Cameroon. AIDS Care. 2016;28(2):205–8.

56. Familiar I, Murray S, Ruisenier-Escudero H, Sikorski A, Nakasujja N, Boivin MJ, et al. Socio-demographic correlates of depression and anxiety among female caregivers living with HIV in rural Uganda. AIDS Care. 2016;28(12):1541–5.

57. Lu B, Preisser JS, Qaqish BF, Suchindran C, Bangdiwala S, Wolfson M. A comparison of two bias-corrected covariance estimators for generalized estimating equations (GEE). Biometrics. 2001;57(1):120–8.

58. Pan W. Akaike information criterion in generalized estimating equations. The Annals of Applied Statistics. 2007;1(2):402–33.

59. Zou GY, Donner A. Extension of the modified Poisson regression model to accommodate two bias-corrected covariance estimators for generalized estimating equations. Biostatistics. 2003;4(4):619–30.

60. Liew K, Calsbeek R. Bias-corrected variance estimators for the generalised estimating equation. Biometrics. 2002;58(3):654–61.

61. Pollack AA, Weiss B, Trung LT. Mental health, life functioning and risk factors among persons exposed to frequent natural disasters and chronic poverty in Vietnam. BJPsych open. 2016;2(3):221–32.

62. Nguyen MS, Reermann P, Loorits D, Ilves P, Jagomaji T, Nguyen T, et al. Association of temporomandibular joint osseous changes with anxiety, depression, and limitation of mandibular function in elderly Vietnamese. East Asian Archives of Psychiatry. 2019;29(1):20–5.

63. Spith A, Kroenen K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.

64. Schmitz S, Adams R, Walsh C. The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis. BMC Med Res Methodol. 2013;12(1):167.

65. Round JM, Lee C, Hanlon JG, Hyetch E, Dyck JRB, Eunich DT. Changes in patient health questionnaire (PHQ-9) scores in adults with medical authorization for cannabis. BMC Public Health. 2020;20(1):987.

66. Liew K, Calsbeek R. Discriminant validity of the patient health questionnaire-9. Med Care. 2014;52(9):S33–57.

67. Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, et al. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled trial. Lancet (London, England). 2018;392(10149):747–59.

68. Srinivasan R, Pearson RM, Johnson S, Lewis G, Lewis G. Maternal perinatal depression and adherence to antiretroviral treatment and quality of life among HIV-infected pregnant women in Ontario, Canada. J Int Assoc Provid AIDS Care. 2016;15(1):23–35.

69. Schmitz S, Adams R, Walsh C. The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis. BMC Med Res Methodol. 2013;12(1):167.

70. Hah JM, Hilmoe H, Schmidt P, McCue R, Trafton J, Clay D, et al. Preoperative factors associated with remote postoperative pain resolution and opioid cessation in a mixed surgical cohort: post hoc analysis of a peripertative gaba-pentin trial. J Pain Res. 2020;13:2959–70.

71. Sheehan DH, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 22:33–quiz 4–57.

72. Francis JM, Helander A, Kapiga SH, Weiss HA, Grosskurth H. Validation of the MINI (DSM IV) tool for the assessment of alcohol dependence among young people in northern Tanzania using the alcohol biomarker phosphatidylethanol (PhET). Int J Environ Res Public Health. 2015;12(1):14021–33.

73. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:127047.

74. Aljassem K, Raboud JM, Hart TA, Benoit A, Su D, Margolese SL, et al. Gender differences in severity and correlates of depression symptoms in people living with HIV in Ontario, Canada. J Int Assoc Provid AIDS Care. 2016;15(1):23–35.

75. Asangbeh SL, Songbivi JL, Ekali GL, Eyoum C, Misellati P. Predictors of depression among participants in a cross-sectional study of a rural health district in North West Cameroon. AIDS Care. 2016;28(2):205–8.

76. Familiar I, Murray S, Ruisenier-Escudero H, Sikorski A, Nakasujja N, Boivin MJ, et al. Socio-demographic correlates of depression and anxiety among female caregivers living with HIV in rural Uganda. AIDS Care. 2016;28(12):1541–5.

77. Lu B, Preisser JS, Qaqish BF, Suchindran C, Bangdiwala S, Wolfson M. A comparison of two bias-corrected covariance estimators for generalized estimating equations. Biometrics. 2007;63(3):935–41.

78. Onyebuchi-Iwudibia O, Brown A. HIV and depression in Eastern Nigeria: the role of HIV-related stigma. AIDS Care. 2014;26(5):653–7.

79. Slot M, Sodemann M, Gabel H, Holmskov J, Laursen T, Rodkjaer L. Factors associated with risk of depression and relevant predictors of screening for depression in clinical practice: a cross-sectional study among HIV-infected individuals in Denmark. HIV Med. 2015;16(7):393–402.

80. Tanner Z, Lachowsky N, Ding E, Samji H, Mull M, Cescon A, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect Dis. 2016;16(1):590.

81. Wouters E, Masquillier C, le Roux BF. The importance of the family: a longitudinal study of the predictors of depression in HIV patients in South Africa. AIDS Behav. 2016;20(8):1591–602.

82. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705–14.
89. McNeish D, Stapleton LM, Silverman RD. On the unnecessary ubiquity of hierarchical linear modeling. Psychol Methods. 2017;22(1):114–40.
90. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67(3):267–77.
91. McCamey R, Warner J, Illiffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7(1):30.
92. Vitasari P, Wahab MNA, Herawan T, Simnadurai SK, Othman A, Awang MG. Assessing of physiological arousal and cognitive anxiety toward academic performance: the application of catastrophe model. Procedia Soc Behav Sci. 2011;30:615–9.
93. Arent SM, Landers DM. Arousal, anxiety, and performance: a reexamination of the Inverted-U hypothesis. Res Q Exerc Sport. 2003;74(4):436–44.
94. Blashill AJ, Bedoya CA, Mayer KH, O’Cleirigh C, Pinkston MM, Remmert JE, et al. Psychosocial syndemics are additively associated with worse ART adherence in HIV-infected individuals. AIDS Behav. 2015;19(6):981–6.
95. Friedman MR, Stall R, Silvestre AJ, Wei C, Shoptaw S, Herrick A, et al. Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study. AIDS (London, England). 2015;29(9):1087–96.
96. Gross R, Bellamy SL, Ratshaa B, Han X, Steenhoff AP, Mosepele M, et al. Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study. Addiction (Abingdon, England). 2017;112(11):73–81.
97. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.
98. Quan VM, Minh NL, Ha TV, Ngoc NP, Vu PT, Celentano DD, et al. Mortality and HIV transmission among male Vietnamese injection drug users. Addiction (Abingdon, England). 2011;106(3):583–9.
99. Hayes-Larson E, Grau LE, Khoshnood K, Barbour R, Khuat OTH, Heimer R. Drug users in Hanoi, Vietnam: factors associated with membership in community-based drug user groups. Harm Reduc J. 2013;10(1):33.

SUPPORTING INFORMATION

Additional Supporting information may be found online in the Supporting Information tab for this article.

Figure S1. Conceptual model and mapping of underlying theories

Table S1. Associations between depression, anxiety symptoms and HIV outcomes at the next visit, taking into account the effect modification by time (Models with interaction terms)

Table S2. Effect modification of baseline viral suppression on the associations between depression, anxiety symptoms and viral suppression

Table S3. Missing data of depression, anxiety symptoms and HIV outcomes at follow-up visits